Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 9,810 Shares of Stock

Key Points

• Gilead CEO Daniel O’Day sold 9,810 shares for about $1.72 million on November 5, under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares; the sale reduced his ownership by 1.75%.
• O’Day also sold more than 102,000 shares on November 4. Gilead’s latest quarterly earnings beat analyst expectations, with EPS of $2.55 and revenue of $8.30 billion.
• Gilead announced a quarterly dividend of $0.82 per share, equivalent to $3.28 annually and a 2.0% yield. Analysts’ average rating is “Moderate Buy,” with an average price target of $170.15.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel O'Day sold 9,810 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $175.17, for a total transaction of $1,718,417.70. Following the sale, the chief executive officer owned 551,683 shares in the company, valued at approximately $96,638,311.11. This trade represents a 1.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O'day also recently made the following trade(s):

• On Wednesday, November 4th, Daniel O'Day sold 102,619 shares of Gilead Sciences stock. The shares were sold at an average price of $175.16, for a total transaction of $17,974,744.04.
• On Monday, November 2nd, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Friday, October 30th, Daniel O'Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O'Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Stock Down 0.4%

GILD traded down $0.68 on Friday, hitting $166.89. 5,817,414 shares of the company were exchanged, compared to its average volume of 6,855,866. The firm has a 50-day moving average price of $152.68 and a two-hundred day moving average price of $140.73. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a market cap of $207.00 billion, a price-to-earnings ratio of -52.81 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.47 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences's dividend payout ratio is presently -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Persistent Asset Partners Ltd acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at $25,000. Kimelman & Baird LLC purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $25,000. PFS Partners LLC raised its stake in Gilead Sciences by 101.1% during the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth $29,000. Finally, Wiser Advisor Group LLC purchased a new stake in Gilead Sciences in the second quarter valued at $30,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Needham & Company LLC set a $175.00 price target on shares of Gilead Sciences in a report on Friday, October 30th. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 29th. Morgan Stanley raised their price objective on shares of Gilead Sciences from $163.00 to $183.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Bank of America lifted their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a "buy" rating in a research report on Tuesday, October 20th. Finally, Cantor Fitzgerald boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $170.15.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead's Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences' Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.